Skip to main content

Ingram Douglas S's Form 4 filing

Sarepta Therapeutics, Inc.SRPT · filed Nov 6, 2023

Accession no.
0001209191-23-054441
Filed
Nov 6, 2023
Trade date
Nov 3, 2023
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market purchases total $2.00M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ingram Douglas SCIK 0001190644Director, Officer (President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 3, 2023Common StockPPurchaseAcquired+10,081$78.57F1+$792,064.17375,163Direct
Nov 3, 2023Common StockPPurchaseAcquired+11,060$79.70F2+$881,482386,223Direct
Nov 3, 2023Common StockPPurchaseAcquired+3,884$80.33F3+$312,001.72390,107Direct
Nov 3, 2023Common StockPPurchaseAcquired+200$81.26+$16,252390,307Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.03 to $79.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.05 to $80.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.08 to $80.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)